Based on the Pak Fah Yeow International Limited stock forecasts from 0 analysts, the average analyst target price for Pak Fah Yeow International Limited is not available over the next 12 months. Pak Fah Yeow International Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Pak Fah Yeow International Limited is Bearish, which is based on 4 positive signals and 10 negative signals. At the last closing, Pak Fah Yeow International Limited’s stock price was HKD 1.28. Pak Fah Yeow International Limited’s stock price has changed by +1.59% over the past week, +0.00% over the past month and -7.25% over the last year.
No recent analyst target price found for Pak Fah Yeow International Limited
No recent average analyst rating found for Pak Fah Yeow International Limited
Company Overview
Pak Fah Yeow International Limited, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and internationally. It operates through three segments: Healthcare, Property Investments, and Treasury Investments. The company offers white flower embrocation medicated oils, strain relief products, and ointments under, as well as Fúzai 239, a floral-scented white flower embrocation. In addition, it invests in commercial, industrial, residential, and car park properties; and provides advertising agency services. The company was founded in 1927 and is headquartered in Wan Chai, Hong Kong. Address: 200 Gloucester Road, Wan Chai, Hong Kong Read Less
Pak Fah Yeow International Limited, together with its subsidiaries, manufactures, markets, and distributes healthcare products under the Hoe Hin brand name in the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and internationally....Read More
Stock Target Advisor's fundamental analysis for Pak Fah Yeow International Limited's stock is Bearish.
0239:HK stock's dividend yield is 4.77%.
Our analysis grades 0239:HK stock's dividend yield at C. This means that 0239:HK stock's dividend yield
is above 76% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the HK exchange.
Based on this 0239:HK may be a average dividend stock for its sector.
Unfortunately we do not have enough data on 0239:HK's stock to indicate what its average analyst target is.
0239:HK stock's Price/Earning ratio is 16.00.
Our analysis grades 0239:HK stock's Price / Earning ratio at F. This means that 0239:HK stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers-Specialty & Generic sector in the HK exchange.
Based on this 0239:HK may be a overvalued for its sector.
The last closing price of 0239:HK's stock was HKD 1.28.
The most recent market capitalization for 0239:HK is HKD 0.40B.
Unfortunately we do not have enough analyst data on 0239:HK's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0239:HK !
Please login to proceed
Sorry - extended search is only available for registered users.
